Biovail Names Scandinavian Licensee for Tiazac.TORONTO--(BW HealthWire)--Sept. 16, 1997-- Bristol Myers Unit A/S GEA GEA - Graph Extended ALGOL. Extension of ALGOL 60 for graph manipulation, on UNIVAC 1108. "A Language for Treating Graphs", S. Crespi-Reghizzi et al, CACM 13(5) (May 1970). Farmaceutisk Fabrik to Market Biovail Corp. International (NYSE NYSE See: New York Stock Exchange , TSE See Tokyo Stock Exchange. TSE 1. See Tokyo Stock Exchange (TSE). 2. See Toronto Stock Exchange (TSE). :BVF BVF Biovail Corporation (stock symbol) BVF Berufsverband der Frauenärzte eV (Muenchen, Germany) BVF Bearing Versus Frequency ) today announced the signing of a licensing agreement with A/S GEA Farmaceutisk Fabrik ("GEA"), a subsidiary of Bristol Myers Squibb, for the marketing of Viazem(R) SR (Tiazac(R) in North America) in Denmark, Finland and Sweden, as well as an option to market in Norway. Viazem(R) SR is the company's once-daily formulation of the calcium channel blocker calcium channel blocker n. Any of a class of drugs that inhibit movement of calcium ions across a cell membrane, used in the treatment of cardiovascular disorders. , diltiazem, used in the treatment of angina pectoris and hypertension. Eugene Melnyk, chairman of the board, commented, "The signing of this agreement with GEA demonstrates the continuing successful progress being made internationally by Viazem(R) with approvals now in eleven European countries and marketing agreements with seven major partners. We are very excited about our prospects in these dynamic markets." Biovail Corp. International is an international full-service pharmaceutical company, engaged in the formulation, clinical testing, registration and manufacture of drug products utilizing advanced drug delivery technologies. -0- "Safe Harbor" statement under the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. To the extent any statements made in this release contain information that is not historical, these statements are essentially forward looking and are subject to risks and uncertainties, including the difficulty of predicting FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. approvals, acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, the regulatory environment, fluctuations in operating results and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission. CONTACT: Biovail Corp. International Eugene Melnyk or Bob Podruzny, 416/285-6000 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion